Evaluation of detecting resistant mutants in lamivudine treated HBV infected by gene chip
10.3760/cma.j.issn.1003-9279.2010.04.017
- VernacularTitle:基因芯片检测拉米夫定治疗乙肝病毒感染耐药分析
- Author:
Chang-Hua ZHENG
1
;
Bing-Fei LI
;
Feng LIN
;
Min-Qiao ZHENG
;
He-Zhi FANG
;
Hong CHEN
;
Li-Min CAI
;
Jian-Yi HOU
Author Information
1. 温州医学院附属温岭医院
- Keywords:
Lamivudine;
Genes;
Mutation
- From:
Chinese Journal of Experimental and Clinical Virology
2010;24(4):289-291
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate of drug resistant mutants tend to be induced in the HBV infected patients treated by lamivudine in this paper, which contributes a new way to direct clinical drug administration. Methods 255 clinical samples from 51 patients treated with lamivudine and 145 sera from HBV DNA negative controls were assayed for HBV mutations utilizing gene chip and the mutations were analysed. Results 10 patients drug resistant mutants were detectd in all 51 patients HBV infected treated by lamivudine, and drug fast rate is19.6% ( 10/51 ), and its virus loading ＞ 105 copes/ml. 4 patients HBeAg were changed negative in the HBV infected patients treated by lamivudine. 10 HBV DNA polymerase mutation was detected, Its 9 mutantion in codon 552 ( YMDD convsev district), 3 mutantion in codon 528and none mutantion in codon 555. There are 4 eligible to detecting wild type HBV and HBV mutants in 5patient's sera and the lower 40% relative proportion of wild type HBV. Two mutantion type virus were detected the (4,4) codon ATT and (3,3) codon TTG in one patient's sera, and its emerged and increased synchronization. Previously unreported (3,3) mutants were found in those samples. Conclusion Upper six months were easily formed drug resistant mutants tend to be induced in the HBV infected patients treated by lamivudine, and its virus loading ＞105 copes/ml. The wild type HBV and HBV mutants mixed viruses infection of YMDD convsev district in patient's sera. The above studies has great potential application of administration for lamivudine treatment in HBV patients.
